Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $114

Benzinga · 3d ago
Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:BNTX) with a Overweight and lowers the price target from $115 to $114.